Skip to main content
SpringerLink
Log in

Cellular and Clinical Pharmacology of Fludarabine

  • Review Articles
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

In the past decade, fludarabine has had a major impact in increasing the effectiveness of treatment of patients with indolent B-cell malignancies. This has come about in a variety of clinical circumstances, including use of fludarabine alone as well as in combinations with DNA-damaging agents or membrane-targeted antibodies. Other strategies have used fludarabine to reduce immunological function, thus facilitating non-myeloablative stem cell transplants.

Fludarabine is a prodrug that is converted to the free nucleoside 9-β-D-arabinosyl-2-fluoroadenine (F-ara-A) which enters cells and accumulates mainly as the 5′-triphosphate, F-ara-ATP. The rate-limiting step in the formation of triphosphate is conversion of F-ara-A to its monophosphate, which is catalyzed by deoxycytidine kinase. Although F-ara-A is not a good substrate for this enzyme, the high specific activity of this protein results in efficient phosphorylation of F-ara-A in certain tissues. F-ara-ATP has multiple mechanisms of action, which are mostly directed toward DNA. These include inhibition of ribonucleotide reductase, incorporation into DNA resulting in repression of further DNA polymerisation, and inhibition of DNA ligase and DNA primase. Collectively these actions affect DNA synthesis, which is the major mechanism of F-ara-A-induced cytotoxicity Secondarily, incorporation into RNA and inhibition of transcription has been shown in cell lines.

With the standard dose of fludarabine (25 to 30 mg/m2/day given over 30 minutes for 5 days), plasma concentrations of about 3 μmol/L F-ara-A are achieved at the end of each infusion. Serial sampling of leukaemia cells from patients receiving these standard doses of fludarabine has demonstrated that the peak concentrations of F-ara-ATP are achieved 4 hours after start of fludarabine infusion. Although there is heterogeneity among individuals with respect to rate of F-ara-ATP accumulation, the peak concentrations are generally proportional to the dose of the drug. Knowledge of the plasma pharmacokinetics of its principal nucleoside metabolite F-ara-A, and the cellular pharmacology of the proximal active metabolite, F-ara-ATP, has provided some understanding of the activity of fludarabine when used as a single agent. Preclinical studies directed toward learning the mechanisms of action of this agent have formed the basis for several mechanism-based strategies for its combination and scheduling with other agents.

As a single agent fludarabine has been effective for the indolent leukaemias. Biochemical modulation strategies resulted in enhanced accumulation of cytarabine triphosphate and led to the use of fludarabine for the treatment of acute leukaemias. Combination of fludarabine with DNA damaging agents to inhibit DNA repair processes has been highly effective for indolent leukaemias and lymphomas. The current review brings together knowledge of the mechanisms of fludarabine, the state of understanding of the plasma pharmacokinetics, and cellular pharmacodynamics of fludarabine nucleotides. This may be useful in the design of future therapeutic approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Table II

Similar content being viewed by others

Notes

  1. Use of tradenames is for product identification only and does not imply endorsement.

References

  1. Montgomery JA, Hewson K. Synthesis of potential anticancer agents X: 2-fluoroadenosine. J Am Chem Soc 1957; 79: 4559–63

    Article  CAS  Google Scholar 

  2. Chilson OP, Fisher JR. Some comparative studies of calf and chicken adenosine deaminase. Arch Biochem Biophys 1963; 102: 77–85

    Article  PubMed  CAS  Google Scholar 

  3. Cory JG, Suhadolnik RJ. Structural requirements for binding by adenosine deaminase. Biochemistry 1965; 4: 1729–32

    Article  Google Scholar 

  4. Frederickson S. Specificity of adenosine deaminase toward adenosine and 2′-deoxyadenosine analogues. Arch Biochem Biophys 1966; 113: 383–9

    Article  Google Scholar 

  5. Skipper HE, Montgomery JA, Thompson JR, et al. Structure-activity relationships and cross-resistance observed on evaluation of a series of purine analogs against experimental neoplasms. Cancer Res 1959; 19: 425–37

    PubMed  CAS  Google Scholar 

  6. Shigeura HT, Boxer GE, Sampson SD, et al. Metabolism of 2-fluoroadenosine by Ehrlich ascites cells. Arch Biochem Biophys 1965; 111:713–9

    Article  PubMed  CAS  Google Scholar 

  7. Parks Jr RE, Brown P. Incorporation of nucleosides into the nucleotide pools of human erythrocytes: adenosine and its analogs. Biochemistry 1983; 12: 3294–302

    Article  Google Scholar 

  8. Zimmerman TP, Rideout JE, Wolberg G, et al. 2-Fluoroadenosine 3′-5′-monophosphate. A metabolite of 2-fluoroadenosine in mouse cytotoxic lymphocytes. J Biol Chem 1976; 251: 6757–66

    PubMed  CAS  Google Scholar 

  9. Montgomery JA, Hewson K. Nucleosides of 2-fluoroadenine. J Med Chem 1969; 12: 498–504

    Article  PubMed  CAS  Google Scholar 

  10. Danhauser L, Plunkett W, Keating M, et al. 9-β-D-Arabino-furanosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia andlymphoma. Cancer Chemother Pharmacol 1996; 18: 145–52

    Google Scholar 

  11. Barrueco JR, Jacobsen DM, Chang C-H, et al. Proposed mechanism of therapeutic selectivity of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells. Cancer Res 1987; 47: 700–6

    PubMed  CAS  Google Scholar 

  12. Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A 1980; 77: 6865–9

    Article  PubMed  CAS  Google Scholar 

  13. Dow LW, Bell DE, Poulakos L, et al. Difference in metabolism and cytotoxicity between 9-β-D-arabinofuranosyladenine and 9-β-D-arabinofuranosyl-2-fluoroadenine in human leukemic lymphoblasts. Cancer Res 1980; 40: 1405–10

    PubMed  CAS  Google Scholar 

  14. Shewach DS, Reynolds KK, and Hertel L. Nucleotide specificity of human deoxycytidine kinase. Mol Pharmacol 1993; 42: 518–24

    Google Scholar 

  15. Krenitsky TA, Tuttle JV, Koszalka GW, et al. Deoxycytidine kinase from calf thymus: substrate and inhibitor specificity. J Biol Chem 1976; 251: 4055–61

    PubMed  CAS  Google Scholar 

  16. Avramis VI, Plunkett W. Metabolism and therapeutic efficacy of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388. Cancer Res 1982; 42: 2587–91

    PubMed  CAS  Google Scholar 

  17. Brockman RW, Schabel Jr FM, Montgomery JA. Biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-D-arabinofuranosyladenine. Biochem Pharmacol 1977; 26: 2193–6

    Article  PubMed  CAS  Google Scholar 

  18. Plunkett W, Alexander L, Chubb S, et al. Comparison of the toxicity and metabolism of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res 1980; 40: 2349–55

    PubMed  CAS  Google Scholar 

  19. Huang P, Plunkett W. Action of 9-β-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism. Mol Pharmacol 1991; 39: 449–55

    PubMed  CAS  Google Scholar 

  20. Spriggs D, Robbins G, Mitchell T, et al. Incorporation of 9-β-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA. Biochem Pharmacol 1986; 35: 247–52

    Article  PubMed  CAS  Google Scholar 

  21. Huang P, Sandoval A, Van Den Neste E, et al. Inhibition of RNA transcription: a biochemical mechanism of fludarabine-in-duced apoptosis in chronic lymphocytic leukemia cells. Leukemia 2000; 14: 1405–13

    Article  PubMed  CAS  Google Scholar 

  22. Plunkett W, Huang P, Gandhi V Metabolism and action of fludarabine phosphate. Semin Oncol 1990; 17 (5 Suppl. 8): 3–17

    PubMed  CAS  Google Scholar 

  23. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine: a mechanism for cytotoxicity. J Biol Chem 1990; 265: 16617–25

    PubMed  CAS  Google Scholar 

  24. Plunkett W, Saunders PP. Metabolism and action of purine nucleoside analogs. Pharmacol Ther 1991; 49: 2339–68

    Article  Google Scholar 

  25. Parker WB, Bapat AR, Shen J-X, et al. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase and ribonucleotide reductase. Mol Pharmacol 1988; 34: 485–91

    PubMed  CAS  Google Scholar 

  26. Tseng WC, Derse D, Cheng Y-C, et al. In vitro activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol 1982; 21: 474–7

    PubMed  CAS  Google Scholar 

  27. White L, Shaddix SC, Brockman RW, et al. Comparison of the actions of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res 1982; 42: 2260–4

    PubMed  CAS  Google Scholar 

  28. Seymour JF, Huang P, Plunkett W, et al. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res 1996; 2: 653–8

    PubMed  CAS  Google Scholar 

  29. Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 1988; 48: 329–34

    PubMed  CAS  Google Scholar 

  30. Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of arabinosylcytosine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993; 11: 116–24

    PubMed  CAS  Google Scholar 

  31. Gandhi V, Huang P, Chapman A, et al. Incorporation of fludarabine and arabinosylcytosine 5′-triphosphates by DNA polymerase α: affinity, interaction, and consequences. Clin Cancer Res 1997; 3: 1347–55

    PubMed  CAS  Google Scholar 

  32. Catapano CV, Perrino FW, Fernandes DJ. Primer RNA chain termination induced by 9-beta-D-arabinofuranosyl-2-fluoro-adenine 5′-triphosphate: a mechanism for DNA synthesis inhibition. J Biol Chem 1993; 268: 7179–85

    PubMed  CAS  Google Scholar 

  33. Parker W, Cheng, Y-C. Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs. Mol Pharmacol 1987; 31: 146–51

    PubMed  CAS  Google Scholar 

  34. Kamiya K, Huang P, Plunkett W. Inhibition of the 3′→5′ ex-onuclease of human DNA polymerase epsilon by fludarabineterminated DNA. J Biol Chem 1996; 271: 19428–35

    Article  PubMed  CAS  Google Scholar 

  35. Lasko DD, Tomkinson AE, Lindahl T. Eukaryotic DNA ligases. Mutat Res 1990; 236: 277–87

    Article  PubMed  CAS  Google Scholar 

  36. Yang S-W, Huang P, Plunkett W, et al. Dual mode of inhibition of purified DNA ligase I from human cells by 9-beta-D-arabinofuranosyl-2-fluoroadenine triphosphate. J Biol Chem 1992; 267: 2345–9

    PubMed  CAS  Google Scholar 

  37. Huang P, Siciliano MJ, Plunkett W. Gene deletion, a mechanism of induced mutation by arabinofuranosyl-2-fluoroadenine. Mutat Res 1989; 210: 291–301

    Article  PubMed  CAS  Google Scholar 

  38. Huang P, Plunkett W Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995; 36: 181–8

    Article  PubMed  CAS  Google Scholar 

  39. Huang P, Robertson LE, Wright S, et al. High molecular weight DNA fragmentation: a critical event in nucleoside analogueinduced apoptosis in leukemia cells. Clin Cancer Res 1995; 1: 1005–13

    PubMed  CAS  Google Scholar 

  40. Huang P, Ballai K, Plunkett W. Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis. Cancer Res 1997; 57: 3407–14

    PubMed  CAS  Google Scholar 

  41. Liu X, Zou H, Slaughter C, et al. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 1997; 89: 175–84

    Article  PubMed  CAS  Google Scholar 

  42. Leoni LM, Chao Q, Cottam HB. Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c. Proc Natl Acad Sci U S A 1998; 95: 9567–71

    Article  PubMed  CAS  Google Scholar 

  43. Genini D, Budihardjo I, Plunkett W, et al. Nucleotide requirement for the in vitro activation of Apaf-1-mediated caspase pathway. J Biol Chem 2000; 275: 29–34

    Article  PubMed  CAS  Google Scholar 

  44. Malspeis L, Grever MR, Staubus AE, et al. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Sem Oncol 1990; 17 (5 Suppl. 8): 18–32

    CAS  Google Scholar 

  45. Hutton JJ, Von Hoff DD, Kuhn J, et al. Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-mono-phosphate (NSC 312887), a new purine antimetabolite. Cancer Res 1984; 44: 4183–6

    PubMed  CAS  Google Scholar 

  46. Danhauser L, Plunkett W, Liliemark J, et al. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate in patient with relapsed leukemia. Leukemia 1987; 1: 638–43

    PubMed  CAS  Google Scholar 

  47. Hersh MR, Kuhn J, Philips JL, et al. Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemother Pharmacol 1986; 17: 277–80

    Article  PubMed  CAS  Google Scholar 

  48. Kemena A, Fernandez M, Bauman J, et al. A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids. Clin Chim Acta 1991; 200: 95–106

    Article  PubMed  CAS  Google Scholar 

  49. Avramis VI, Champagne J, Sato J, et al. Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res 1990; 50: 7226–31

    PubMed  CAS  Google Scholar 

  50. Avramis VI, Wiersma S, Krailo MD, et al. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. Clin Cancer Res 1998; 4: 45–52

    PubMed  CAS  Google Scholar 

  51. Leiby JM, Grever MR, Staubus MR, et al. Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous infusion schedule. J Natl Cancer Inst 1988; 80: 447–9

    Article  PubMed  CAS  Google Scholar 

  52. Kemena A, Keating MJ, Plunkett W. Plasma and cellular bioavailability of oral fludarabine [abstract]. Blood 1991; 78: 52a

    Google Scholar 

  53. Kemena A, O’Brien S, Kantarjian H, et al. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymphoma 1993; 10: 187–93

    Article  PubMed  CAS  Google Scholar 

  54. Robertson LE, O’Brien S, Kantarjian H, et al. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 1995; 9: 1444–9

    PubMed  CAS  Google Scholar 

  55. Ross SR, McTavish D, Faulds D. Fludarabine: a review of its pharmacological properties and therapeutic potential in malignancy. Drugs 1993; 45: 737–59

    Article  PubMed  CAS  Google Scholar 

  56. Plunkett W, Gandhi V. Cellular metabolism of nucleoside analogs in CLL: implications for drug development. In: Cheson B, editor. Chronic lymphocytic leukemia — scientific advances and clinical developments. New York: Marcel Dekker Inc, 1992: 197–219

    Google Scholar 

  57. Plunkett W, Gandhi V, Huang P, et al. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapy. Semin Oncol 1993; 20 (5 Suppl. 7): 2–12

    PubMed  CAS  Google Scholar 

  58. Gandhi V, Kemena A, Keating MJ, et al. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 1992; 52: 897–903

    PubMed  CAS  Google Scholar 

  59. Kemena A, Gandhi V, Shewach DS, et al. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy. Cancer Chemother Pharmacol 1992; 31: 193–9

    Article  PubMed  CAS  Google Scholar 

  60. Gandhi V, Kemena A, Keating MJ, et al. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma 1993; 10: 49–56

    Article  PubMed  CAS  Google Scholar 

  61. Keating MJ, O’Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878–84

    PubMed  CAS  Google Scholar 

  62. Keating MJ, O’Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165–71

    PubMed  CAS  Google Scholar 

  63. Gandhi V, Estey E, Keating MJ, et al. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 1996; 87: 156–64

    Google Scholar 

  64. Gandhi V, Plunkett W, Kantarjian H, et al. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during phase I clinical trial in chronic myelogenous leukemia. J Clin Oncol 1998; 16: 2321–31

    PubMed  CAS  Google Scholar 

  65. Gandhi V, Estey E, Du M, et al. Minimum dose of fludarabine for maximal modulation of arabinosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res 1997; 3: 1539–45

    PubMed  CAS  Google Scholar 

  66. Malspeis L, Staubus AE, Lyon ME, et al. Oral bioavailability of 2-F-ara-A from fludarabine phosphate capsules in dogs [abstract]. Proc Am Assoc Cancer Res 1989; 30: 534

    Google Scholar 

  67. Foran JM, Oscier D, Orchard J, et al. A pharmacokinetic study of single doses of oral fludarabine phosphate. J Clin Oncol 1999; 17: 1574–9

    PubMed  CAS  Google Scholar 

  68. Boogaerts MA, Van Hoof A, Catovsky D, et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 4252–8

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Supported in part by grants CA32839, CA55164, and CA57629 from the National Cancer Institute, Department of Health and Human Services. The authors gratefully acknowledge the excellent technical assistance of Sherri Chubb, Billie Nowak, Min Du, Mary Ayres and Theresa Adams.

Author information

Authors and Affiliations

  1. Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 71, Houston, Texas, 77030, USA

    Varsha Gandhi & William Plunkett

Authors
  1. Varsha Gandhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William Plunkett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Varsha Gandhi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gandhi, V., Plunkett, W. Cellular and Clinical Pharmacology of Fludarabine. Clin Pharmacokinet 41, 93–103 (2002). https://doi.org/10.2165/00003088-200241020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200241020-00002

Keywords

Search

Navigation